Zymes, LLC – Trademark Portfolio
Entity Type: 16
Zymes, LLC holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include UBISOL and UBISOL-AQUA. The owner is based in Hasbrouck Heights, NJ.
777 Terrace Avenue
Hasbrouck Heights, NJ 07604
Showing of trademarks Trademarks
Trademark Classifications
Zymes, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Zymes, LLC have?
Zymes, LLC has 18 U.S. trademarks filed with the USPTO. Of these, 2 registered, 13 abandoned, 3 cancelled.
What trademark classes does Zymes, LLC file in?
Zymes, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 32 (Light Beverages), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Zymes, LLC's most well-known trademarks?
Zymes, LLC's registered trademark portfolio includes well-known marks such as UBISOL and UBISOL-AQUA. These are among 2 currently registered trademarks in the portfolio.
What is Zymes, LLC's trademark registration success rate?
Zymes, LLC has a 11% trademark registration rate, with 2 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.